<?xml version='1.0' encoding='utf-8'?>
<document id="27686971"><sentence text="Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations."><entity charOffset="17-26" id="DDI-PubMed.27686971.s1.e0" text="Erlotinib" /></sentence><sentence text="First-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment of advanced non-small-cell lung cancer with EGFR-activating mutations improves outcomes compared with chemotherapy, but resistance develops in most patients"><entity charOffset="51-59" id="DDI-PubMed.27686971.s2.e0" text="tyrosine" /></sentence><sentence text=" Compensatory signaling through type 1 insulin-like growth factor 1 receptor (IGF-1R) may contribute to resistance; dual blockade of IGF-1R and EGFR may improve outcomes" /><sentence text="" /><sentence text="We performed a randomized, double-blind, placebo-controlled phase II study of linsitinib, a dual IGF-1R and insulin receptor tyrosine kinase inhibitor, plus erlotinib versus placebo plus erlotinib in chemotherapy-naive patients with EGFR-mutation positive, advanced non-small-cell lung cancer"><entity charOffset="78-88" id="DDI-PubMed.27686971.s5.e0" text="linsitinib" /><entity charOffset="125-133" id="DDI-PubMed.27686971.s5.e1" text="tyrosine" /><entity charOffset="157-166" id="DDI-PubMed.27686971.s5.e2" text="erlotinib" /><entity charOffset="187-196" id="DDI-PubMed.27686971.s5.e3" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e0" e2="DDI-PubMed.27686971.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e0" e2="DDI-PubMed.27686971.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e0" e2="DDI-PubMed.27686971.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e0" e2="DDI-PubMed.27686971.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e1" e2="DDI-PubMed.27686971.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e1" e2="DDI-PubMed.27686971.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e1" e2="DDI-PubMed.27686971.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e2" e2="DDI-PubMed.27686971.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27686971.s5.e2" e2="DDI-PubMed.27686971.s5.e3" /></sentence><sentence text=" Patients received linsitinib 150 mg twice daily or placebo plus erlotinib 150 mg once daily on continuous 21-day cycles"><entity charOffset="19-29" id="DDI-PubMed.27686971.s6.e0" text="linsitinib" /><entity charOffset="65-74" id="DDI-PubMed.27686971.s6.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27686971.s6.e0" e2="DDI-PubMed.27686971.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27686971.s6.e0" e2="DDI-PubMed.27686971.s6.e1" /></sentence><sentence text=" The primary end point was progression-free survival" /><sentence text="" /><sentence text="After randomization of 88 patients (44 each arm), the trial was unblinded early owing to inferiority in the linsitinib arm" /><sentence text=" The median progression-free survival for the linsitinib versus the placebo group was 8" /><sentence text="4 months versus 12" /><sentence text="4 months (hazard ratio, 1" /><sentence text="37; P = " /><sentence text="29)" /><sentence text=" Overall response rate (47" /><sentence text="7% vs" /><sentence text=" 75" /><sentence text="0%; P = " /><sentence text="02) and disease control rate (77" /><sentence text="3% vs" /><sentence text=" 95" /><sentence text="5%; P = " /><sentence text="03) were also inferior" /><sentence text=" Whereas most adverse events were ≤ grade 2, linsitinib plus erlotinib was associated with increased adverse events that led to decreased erlotinib exposure (median days, 228 vs"><entity charOffset="61-70" id="DDI-PubMed.27686971.s24.e0" text="erlotinib" /><entity charOffset="138-147" id="DDI-PubMed.27686971.s24.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27686971.s24.e0" e2="DDI-PubMed.27686971.s24.e0" /><pair ddi="true" e1="DDI-PubMed.27686971.s24.e0" e2="DDI-PubMed.27686971.s24.e1" /></sentence><sentence text=" 305)" /><sentence text=" No drug-drug interaction was suggested by pharmacokinetic and pharmacodynamic results" /><sentence text="" /><sentence text="Adding linsitinib to erlotinib resulted in inferior outcomes compared with erlotinib alone"><entity charOffset="7-17" id="DDI-PubMed.27686971.s28.e0" text="linsitinib" /><entity charOffset="21-30" id="DDI-PubMed.27686971.s28.e1" text="erlotinib" /><entity charOffset="75-84" id="DDI-PubMed.27686971.s28.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27686971.s28.e0" e2="DDI-PubMed.27686971.s28.e0" /><pair ddi="false" e1="DDI-PubMed.27686971.s28.e0" e2="DDI-PubMed.27686971.s28.e1" /><pair ddi="false" e1="DDI-PubMed.27686971.s28.e0" e2="DDI-PubMed.27686971.s28.e2" /><pair ddi="false" e1="DDI-PubMed.27686971.s28.e1" e2="DDI-PubMed.27686971.s28.e1" /><pair ddi="false" e1="DDI-PubMed.27686971.s28.e1" e2="DDI-PubMed.27686971.s28.e2" /></sentence><sentence text=" Further understanding of the signaling pathways and a biomarker that can predict efficacy is needed prior to further clinical development of IGF-1R inhibitors in lung cancer" /><sentence text="" /></document>